Pictilisib (GDC-0941)

目录号：S1065 别名： RG7321

Pictilisib (GDC-0941) Chemical Structure

Molecular Weight(MW): 513.64

Pictilisib (GDC-0941) 是一种有效的PI3Kα/δ抑制剂，在无细胞试验中IC50为 3 nM，对p110β (11倍)和p110γ (25倍)具有适度的选择性。Phase 2。

规格 价格 库存 购买数量  
RMB 1972.48 现货
RMB 986.88 现货
RMB 1390.74 现货
RMB 3026.17 现货
RMB 7926.11 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户购买Selleck的此次产品后发表的文献59篇：

客户使用该产品的9个实验数据：

  • Clonogenic assays of TNBC cell lines grown continuously in increasing concentrations of palbociclib, divided by gene expression subtypes: LAR, luminal androgen receptor; MSL, mesenchymal stem-like; MES, mesenchymal and basal-like. All cell lines are RB1 wild-type except RB1 mutant BT549.

    Clin Cancer Res, 2017, 23(18):5561-5572. Pictilisib (GDC-0941) purchased from Selleck.

    Dual PI3K/BRAF inhibition upregulates BIM and enhances apoptosis in PTEN cells. A, left, Western blot of 1205Lu cells treated with PLX4720 (3 μmol/L, 48 hours), the PI3K inhibitor GDC-0941 (3 μmol/L, 48 hours), or both drugs in combination (PtG); right, immunofluorescence staining of BIM (green) and DAPI (blue) in PTEN cells following PLX4720 treatment (3 μmol/L, 48 hours), the PI3K inhibitor LY294002 (10 μmol/L, 48 hours), or both drugs in combination (PLXtLY). B, left, immunofluorescence staining of PTEN 1205Lu following combined inhibition (3 μmol/L PLX4720 t 10 μmol/L LY294002, 48hours) increases nuclear localization of FOXO3a (green). DAPI is shown in blue. Magnification 40. Right, combined inhibition (3 μmol/L PLX4720 t 10 μmol/L LY294002, 48 hours) increases PTEN WM793 BIM mRNA levels to those observed with single BRAF inhibition (3 μmol/L PLX4720, 48 hours) in the PTENt WM35. C, PTEN cells were treated with PLX4720 (3 μmol/L, 48 hours), GDC-0941 (3 μmol/L, 48hours), or a combination of the 2 drugs (3Pt3G) before Annexin-V staining was analyzed by flow cytometry (*, P < 0.05 between the drug combination and each inhibitor alone). D, combined BRAF/PI3K inhibitor treatment blocks the escape of 1205Lu cells (PTEN) from therapy. Spheroids of 1205Lu cells were treated with either PLX4720 alone (3 and 10 μmol/L: data shows 3 mmol/L), LY294002 (10 μmol/L) alone or a combination of the 2 drugs for 72 hours. In other studies, spheroids were treated with drugs for 72 hours and then allowed to recover for 120 hours. Micrograph shows viability staining (green= live cells, red= dead cells). Magnification 10×.

    Cancer Res 2011 71, 2750-2760. Pictilisib (GDC-0941) purchased from Selleck.

  • Combination of rapamycin and PI-103 leads to the suppression of AKT phosphorylation (phospho-specific western blot). Mel-Juso and 518A2 cells were treated with GDC-0941 from 0.05–1 μmol/L alone and in combination with rapamycin (50 nmol/L) for 24 hours. Control treatment was with DMSO.

     

     

    J Inves Der 2010 131, 495-503. Pictilisib (GDC-0941) purchased from Selleck.

    Growth inhibition induced by the FGFR inhibitor BGJ398 and the PI3K inhibitors alone or in combination. AN3CA (A-C), JHUEM2 (D-F) and MFE296 (G-I) cells were treated with the indicated doses of BGJ398, GDC-0941 a n d BYL719 alone or in combination for 96 hours and an Sulforhodamine B (SRB) assay was subsequently performed. Data are presented as a percentage of the control, in which cells were treated with 0.1% (v/v) DMSO. Points represent the mean of three independent experiments (each performed in triplicate). Error bars represent the standard error of the mean (SEM) and lines were fitted using non-linear regression analysis. Interaction of BGJ398 and GDC-0941(redcircles) or BYL719(blacksquares) in AN3CA(C), JHUEM2(F) and MFE296(I). Median effect analysis was used to evaluate the interaction between the inhibitor combinations. Horizontal dotted lines indicate the boundaries for each interaction classification.

    Mol Cancer Ther, 2017, 16(4):637-648. Pictilisib (GDC-0941) purchased from Selleck.

  • TGF-β induces mTORC2 activation. ( A ) NMuMG cells were treated with TGF-β for the indicated times before lysis and immunoblotting. (B ) NMuMG cells were treated or not with TGF-β for the indicated times, in the presence or absence of SB431542 or LY294002. Cell lysates were subjected to anti-Rictor immunoprecipitation, and the immunoprecipitates were subjected to in vitro kinase assays using kinase-inactive Akt1 as a substrate, before immunoblotting of the kinase reactions, immunoprecipitates and cell lysates. The left panels are from the same gel, without differential exposure. ( C ) NMuMG cells were treated or not with TGF-β or insulin for the indicated times, in the presence or absence of SB431542 or GDC-0941. The kinase activity of mTORC2 was then assessed as in B. The top panels are from the same gel, without differential exposure. (D) NMuMG cells were treated or not with TGF-β for the indicated times, in the presence or absence of SB431542 or LY294002. Cell lysates were subjected to immunoprecipitation using Rictor antibody, and/or immunoblotted.

    J Cell Sci 2012 125(Pt 5), 1259-73. Pictilisib (GDC-0941) purchased from Selleck.

    Effects of LY294002 and GDC-0941 on the high-glucose-induced plasma membrane translocation of DGK δ1. (A, C) HEK293 cells were transfected with pAcGFP-DGKδ1 or pAcGFP-C1 vector. After being glucose-starved for 2.5 h and the subsequent pretreatment with (A) 10 μM LY294002 (Sigma-Aldrich) or (C) 1 μM GDC-0941 (Selleck Chemicals) for 30 min, the cells were incubated with or without high glucose (25 mM) for 5 min. The cells were fixed with 3.7% formaldehyde and observed using confocal laser-scanning microscopy. Scale bar = 10 μm. (B, D) After treatment with (B) LY294002 or (D) GDC-0941, the percentages of cells exhibiting the translocation of AcGFP-tagged DGK δ 1 to the plasma membrane were scored. More than 20 cells ex-pressing AcGFP-tagged DGK δ1 were counted in each experiment. The results are the means ± S.D. of three independent experiments. The statistical significance was deter-mined using Student's t -test (** P < 0.01, *** P < 0.005)

    Biochim Biophys Acta 2012 1823, 2210-6. Pictilisib (GDC-0941) purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of GDC-0941  for 3h,followed by 15-minute  stimulation of 100ng/ml EGF.

     

     

     

    Dr. Zhang of Tianjin Medical University. Pictilisib (GDC-0941) purchased from Selleck.

    We treated all of drugs in T47D which has a PI3KCA H1044R mutation with the concentration shown below for 1 hour and performed western blot analysis using antibodies to phospho-AKT(SERINE 472), and total AKT.

     

     

    Saraswati Sukumar of Johns Hopkins University School of Medicine. Pictilisib (GDC-0941) purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    Pictilisib (GDC-0941) purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Pictilisib (GDC-0941) 是一种有效的PI3Kα/δ抑制剂，在无细胞试验中IC50为 3 nM，对p110β (11倍)和p110γ (25倍)具有适度的选择性。Phase 2。
靶点
p110α [1]
(Cell-free assay)		 p110δ [1]
(Cell-free assay)		 p110β [1]
(Cell-free assay)		 p110γ [1]
(Cell-free assay)		 mTOR [1]
(Cell-free assay)
3 nM 3 nM 33 nM 75 nM 0.58 μM(Ki app)
体外研究

GDC-0941也等效作用于PI3Kα和 PI3Kδ和PI3Kα突变型E545-K和H1047-R,也选择性作用于PI3Kβ(10倍)和 PI3Kγ(25倍), 选择性更高地作用于PI3K II, III, 和IV类成员，包括, C2β, Vps34, DNA-PK和mTOR。GDC-0941 作用于U87MG, PC3, 和 MDA-MB-361 细胞，有效抑制Akt磷酸化，IC50分别为46 nM, 37 nM,和 28 nM。GDC-0941抑制U87MG, A2780, PC3, 和MDA-MB-361细胞增殖，IC50分别为 0.95 μM, 0.14 μM, 0.28 μM, 和0.72 μM。[1]GDC-0941处理，有效抑制对Trastuzumab敏感和不敏感的HER2扩增细胞增殖，IC50为149-944 nM,与 Trastuzumab敏感性无关。GDC-0941抑制含PIK3CA突变的HER2扩增的细胞增殖，IC50<500 nM, 且有效抑制抗trastuzumab 的HER2 扩增乳腺癌细胞增殖和活力。[2]GDC-0941 显著抑制HCT116, DLD1和 HT29细胞生长，GI50分别为1081 nM, 1070 nM 和157 nM。[4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Sf9 MXHLbY5ie2ViQYPzZZk> M2O0blEhcA>? NHXOT2VFVVOR M3\yb2lvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUFmzT{BxOTFyZHXseIEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDjc4V5eHKnc4PpcocheDh3YXzwbIEhf2m2aDDJR|UxKG:oIECuNFA{KM7:TR?= MknMNVg4PTR4NUS=
Sf9 MYHLbY5ie2ViQYPzZZk> M3zuUFEhcA>? M{T6cWROW09? MlPrTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCkZYThJGgyODR5LWKgcZV1[W62IHX4dJJme3OnZDDpckBU\jliY3XscJMh[2:neIDy[ZN{cW6pIIC4OYFteGijIIfpeIghUUN3MDDv[kAxNjByMzFOwG0> M13nZlE5PzV2NkW0
Sf9 MkW3T4lv[XOnIFHzd4F6 MV[xJIg> NHPWOFBFVVOR NU\pd5pKUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDi[ZRiKEV3NEWtT{BufXSjboSg[ZhxemW|c3XkJIlvKFOoOTDj[YxteyClb3X4dJJme3OrbnegdFg2[WyyaHGge4l1cCCLQ{WwJI9nKDBwMECzJO69VQ>? MknDNVg4PTR4NUS=
Sf9 Mn\uT4lv[XOnIFHzd4F6 NFu5UJkyKGh? M33ZXmROW09? NWrsVIxGUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDi[ZRiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZ49mgHC{ZYPzbY5oKHB6NXHsdIhiKHerdHigTWM2OCCxZjCwMlA{OyEQvF2= NVP2fXQ6OTh5NUS2OVQ>
Sf9 M3zaZmtqdmG|ZTDBd5NigQ>? MlvvNUBp NWDt[3lITE2VTx?= M1vPNWlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUFmzT{BxOTFyYXzwbIEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDjc4V5eHKnc4PpcocheDh3YXzwbIE> M{HoTlE5PzV2NkW0
MDA-MB-361 MmLmSpVv[3Srb36gRZN{[Xl? NGnKOlkzKGh? NFHwb4FFVVOR NWDufI86UW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDNSGEuVUJvM{[xJINmdGy|IIfpeIghWEmNM1PBJGU2PDVvSzDteZRifGmxbjD3bZRpKEmFNUCgc4YhOC5yMkig{txO MkK4NVg4PTR4NUS=
PC3 MXPGeY5kfGmxbjDBd5NigQ>? MUSyJIg> NGTFVItFVVOR NUTSRoRTUW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDpckBRXEWQLX71cIwhcHWvYX6gVGM{KGOnbHzzJJdqfGhiSVO1NEBw\iByLkCzO{DPxE1? NHqwdGcyQDd3NE[1OC=>
U87MG MmDISpVv[3Srb36gRZN{[Xl? NEPuengzKGh? NIWzUYpFVVOR Mn;UTY5pcWKrdHnvckBw\iCDa4SgV4VzPDd|IIDoc5NxcG:{eXzheIlwdiCrbjDQWGVPNW63bHygbJVu[W5iVUi3UWch[2WubIOge4l1cCCLQ{WwJI9nKDBwMES2JO69VQ>? M1PTTFE5PzV2NkW0
MDA-MB-361 NW\YWGtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C3N|k3KGh? NULkZZFnTE2VTx?= MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0{PjFiY3XscJMhf2m2aDDQTWs{S0FiRUW0OU1MKG23dHH0bY9vKHerdHigTWM2OCCxZjCwMlczKM7:TR?= NEfj[o8yQDd3NE[1OC=>
A2780 NYHiSHdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f3VFk3KGh? M{HDNmROW09? NEn6WINCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGyO|gxKGOnbHzzJJdqfGhiUFnLN2NCKGGwZDDQWGVPKG23dHH0bY9vKHerdHigTWM2OCCxZjCwMlE1KM7:TR?= MormNVg4PTR4NUS=
PC3 NYf6[3VlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEOwTo86PiCq M3nocGROW09? NEHBR2RKSzVyPUCuNlgh|ryP MWKxPFc2PDZ3NB?=
U87MG NX7qNYJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjB[2E6PiCq MmDsSG1UVw>? MVfJR|UxRTBwOUWg{txO MofuNVg4PTR4NUS=
Sf9 NEnzN4dMcW6jc3WgRZN{[Xl? MoHtN|AhdWmw NV3icZNPTE2VTx?= MVLJcohq[mm2aX;uJI9nKGi3bXHuJHBKO0upYX3tZUBmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNiYX3veY51KG:oIFHUVEBkd26|dX3l[EB4cXSqIFnDOVAhd2ZiMD6wOFIh|ryP NFr4bo0zOjV2OEO0Ni=>
RAW 264.7 NUHSOGxJU2mwYYPlJGF{e2G7 M3fNOFkxKG2rbh?= M{DsO2ROW09? MofFTY5pcWKrdHnvckBw\iCqdX3hckBRUTONZ3HtcYEh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhSUuWIIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4zQThizszN MVyyNlU1QDN2Mh?=
Sf9 NF;y[ZpMcW6jc3WgRZN{[Xl? MnrkNUBp NYXMUWhGUW6qaXLpeIlwdiCxZjDHV3Qu\nW|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2KndHGg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|IHnu[oVkfGWmIGPGPUBk\WyuczD3bZRpKEmFNUCgc4YhOC5yMUeg{txO MmXwNlM2PDB4NEW=
Sf9 NGPaSnhMcW6jc3WgRZN{[Xl? MYCxJIg> M1mzNWlvcGmkaYTpc44hd2ZiR2PUMYZ2e2WmIHj1cYFvKHKnY3;tZolv[W62IGDJN2tl\Wy2YTDlfJBz\XO|ZXS= NH3oTpIzOzV2ME[0OS=>
Sf9 MlP1T4lv[XOnIFHzd4F6 M1Ts[FEhcA>? MkDNTY5pcWKrdHnvckBw\iCJU2St[pV{\WRiaIXtZY4hemWlb33ibY5idnRiUFmzT4didW2jIHX4dJJme3OnZB?= Moj1NlM2PDB4NEW=
Sf9 MmTnT4lv[XOnIFHzd4F6 MkSzNUBp MUHJcohq[mm2aX;uJI9nKEeVVD3meZNm\CCqdX3hckBz\WOxbXLpcoFvfCCSSUPLZYxxcGFiZYjwdoV{e2Wm Mn\qNlM2PDB4NEW=
SKOV3 M3LabmtqdmG|ZTDBd5NigQ>? NEn4SIcyKM7:TR?= NFPxXJUyKGh? NYDJRlBCTE2VTx?= NHfs[pFKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:w M1rYXFI{OzZyM{S4
MCF7 NHLL[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK2b28yKM7:TR?= M3THZVk3KGh? M2K4bGROW09? M4rlT2dKPTB;MD6wO|AzKM7:TR?= MlrtNlM{PjB|NEi=
SKOV3 NVTGVJN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrLNUDPxE1? MlrIPVYhcA>? MnTsSG1UVw>? MWHHTVUxRTBwMUS3OkDPxE1? M3fvWVI{OzZyM{S4
PC3 M37ScWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7zbVZJPzJiaB?= MlLvSG1UVw>? M3rneGlEPTB;MD6yPEDPxE1? MViyNVk5OTdzNB?=
MCF7.1 MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmGyO|IhcA>? NFXpV4dFVVOR MmCxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPQ1[3MlEh[2WubIOg[ZhxemW|c3nu[{BJTVJ{IHflcoUhf2m2aDDJR|UxKG:oIECuNlgh|ryP MVKyNVk5OTdzNB?=
MCF7-neo/Her2 NHzSXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVS3NkBp MmThSG1UVw>? M2fE[2lEPTB;MD6yPUDPxE1? MmrCNlM3PjJ7MEO=
MCF7-neo/Her2 NWXteItFU2mwYYPlJGF{e2G7 NVTmPXZqUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIFHLWEBxcG:|cHjvdplt[XSrb36gZZQhWzR5MzD3bZRpKEmFNUCgc4YhOC5yMEeg{txO NHLTUnEzOzZ4MkmwNy=>
PC3 NIm4RZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzGO|IhcA>? NG\DWoFFVVOR M{nWfWVEPTB;MD6zOEDPxE1? MmDWNlE6QDV4M{m=
MCF7.1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe2bolqPzJiaB?= M4rxV2ROW09? NUfDeI9lSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4NjFiY3XscJMh\XiycnXzd4lv\yCSSUPLZYxxcGFibYX0ZY51KHerdHigSWM2OCCxZjCwMlM6KM7:TR?= NYLvOpdFOjF7OEW2N|k>
PC3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYK3NkBp M4L2SWROW09? NX\0XpBFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOg[IVncWOrZX70JIlvKFCWRV6ge4l1cCCLQ{WwJI9nKDBwM{mg{txO NYHUN2QzOjByNUC2Olk>
MCF7.1 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\RfVczKGh? NIfBVZRFVVOR MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkeuNUBk\WyuczDlfJBz\XO|aX7nJHBKO0ujbIDoZUBufXSjboSge4l1cCCLQ{WwJI9nKDBwM{Sg{txO MVKyNFA2ODZ4OR?=
MCF7.1 NEHjS|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jJc|czKGh? MX3FR|UxRTBwN{Kg{txO MVuyNFM1PjZ3Nh?=
NCI-H1975 Mon5R5l1d3SxeHnjJGF{e2G7 NIftRmI4OiCq MWTJR|UxRTBwMkeg{txO M4i2XVI{ODV7NUS1
H460 NI\hVVdEgXSxdH;4bYMhSXO|YYm= M4nmfVczKGh? M{LO[GlEPTB;MD64O{DPxE1? M4f1UFI{ODV7NUS1
HT-29 M{XCPWN6fG:2b4jpZ{BCe3OjeR?= M2TQPVczKGh? MXHJR|UxRTBwNk[g{txO NUiwSWFIOjNyNUm1OFU>
HepG2 MV;DfZRwfG:6aXOgRZN{[Xl? NGXrUFI4OiCq NFjBdXVKSzVyPUGg{txO MknLNlMxPTl3NEW=
SGC7901 MV3DfZRwfG:6aXOgRZN{[Xl? NGmxU4w4OiCq NHvjdoxKSzVyPUGuPEDPxE1? M2nF[lI{ODV7NUS1
NCI-H226 MVHDfZRwfG:6aXOgRZN{[Xl? MoXQO|IhcA>? MWnJR|UxRTJwOTFOwG0> M13BZVI{ODV7NUS1
A549 NYrpSoxmS3m2b4TvfIlkKEG|c3H5 MWO3NkBp M3vYNmlEPTB;Nj65JO69VQ>? NXK0OIF7OjNyNUm1OFU>
U87MG M4nJVWN6fG:2b4jpZ{BCe3OjeR?= M1\WdFczKGh? MoDhTWM2OD15Lke3JO69VQ>? MnrqNlMxPTl3NEW=
HBC4 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrsc4dIUTVyPT22MlA{KE1? NUfOTZhtOjJ|M{[yOFY>
BSY1 M3P2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkWzcI9oT0l3ME2tOk46OCCP MoXBNlI{OzZ{NE[=
HBC5 M4nmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHv2emFtd2eJSUWwQU03NjZyIF2= NXv4WZhOOjJ|M{[yOFY>
MCF7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e3Roxw\0eLNUC9MVcvOzNiTR?= NEnnS5IzOjN|NkK0Oi=>
MDA-MB-231 NVXIOXpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnn2cI9oT0l3ME2tOU41PiCP M3\rdFIzOzN4MkS2
U251 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S4S4xw\0eLNUC9MVUvPTBiTR?= MYCyNlM{PjJ2Nh?=
SF268 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP2cI9oT0l3ME2tOU4{QSCP MXiyNlM{PjJ2Nh?=
SF295 MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;pcI9oT0l3ME2tOk4{PyCP NELmXYUzOjN|NkK0Oi=>
SF539 M4qxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\hZ3htd2eJSUWwQU03NjVyIF2= NIXjZYczOjN|NkK0Oi=>
SNB75 NFTlN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DGfoxw\0eLNUC9MVcvOTBiTR?= M3XNTlIzOzN4MkS2
SNB78 MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXOwVmJ3dG:pR1m1NF0uPi53MjDN NEPEc2ozOjN|NkK0Oi=>
HCC2998 NYWzUVdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK3cI9oT0l3ME2tOk4zQSCP NUnDNJl7OjJ|M{[yOFY>
KM12 NHHTW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHOwV4Ntd2eJSUWwQU02Njd4IF2= M{\iVFIzOzN4MkS2
HT-29 Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Pld4xw\0eLNUC9MVYvOzBiTR?= NXnze2QzOjJ|M{[yOFY>
HCT15 MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTyUnN[dG:pR1m1NF0uPi5zMjDN NXS1TJA3OjJ|M{[yOFY>
HCT116 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3qwU4xw\0eLNUC9MVUvQDdiTR?= MXmyNlM{PjJ2Nh?=
NCI-H23 M3fSe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFz2SZBtd2eJSUWwQU02Njd|IF2= NGnPU5ozOjN|NkK0Oi=>
NCI-H226 MnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nOUYxw\0eLNUC9MVYvOjFiTR?= M{THWVIzOzN4MkS2
NCI-H522 M2TxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7sc4dIUTVyPT22MlU5KE1? M360VlIzOzN4MkS2
NCI-H483 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDzOnJtd2eJSUWwQU03NjV4IF2= MV2yNlM{PjJ2Nh?=
A549 M3PCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrsc4dIUTVyPT22MlE2KE1? MW[yNlM{PjJ2Nh?=
DMS273 NWfvNlJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlKwcI9oT0l3ME2tOk41OyCP NYPwXZpROjJ|M{[yOFY>
DMS114 M2\rfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\Q[oxw\0eLNUC9MVUvQTJiTR?= M4TmO|IzOzN4MkS2
LOXIMVI MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;m[oxw\0eLNUC9MVYvOjliTR?= NUXuTZZTOjJ|M{[yOFY>
OVCAR3 NWfPdHNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXsc4dIUTVyPT22MlcyKE1? MYmyNlM{PjJ2Nh?=
OVCAR4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S1UYxw\0eLNUC9MVUvPzZiTR?= NV;YdWtQOjJ|M{[yOFY>
OVCAR5 NI\3UWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXtcI9oT0l3ME2tOk4zPiCP NF:0V3czOjN|NkK0Oi=>
OVCAR8 Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInIfpJtd2eJSUWwQU02Njd|IF2= MoKwNlI{OzZ{NE[=
SKOV3 M4rXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEe0Xoptd2eJSUWwQU03NjV{IF2= M4XEelIzOzN4MkS2
RXF631L MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTsc4dIUTVyPT22Mlg5KE1? MmnoNlI{OzZ{NE[=
ACHN NIP5PZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzYZY1td2eJSUWwQU03NjB5IF2= MY[yNlM{PjJ2Nh?=
St-4 NHLuOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33he4xw\0eLNUC9MVUvPTZiTR?= MXqyNlM{PjJ2Nh?=
MKN1 MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnZ[XJtd2eJSUWwQU04NjB6IF2= M36zU|IzOzN4MkS2
MKN7 NFznbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XzO4xw\0eLNUC9MVYvPTBiTR?= MV:yNlM{PjJ2Nh?=
MKN28 MmDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3mOYlPdG:pR1m1NF0uPS53MjDN M{\w[FIzOzN4MkS2
MKN45 M3i1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zoOoxw\0eLNUC9MVYvPTViTR?= MWiyNlM{PjJ2Nh?=
MKN74 NHX5Xo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFKxbohtd2eJSUWwQU03NjB{IF2= MlfsNlI{OzZ{NE[=
DU145 M4\LNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon0cI9oT0l3ME2tOU45PSCP MXSyNlM{PjJ2Nh?=
PC3 NXfZRoR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L6O4xw\0eLNUC9MVYvPjZiTR?= NFfmS2IzOjN|NkK0Oi=>
ES5 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHQZoJjUUN3ME21NE4zOSCwTR?= M1HDUHNCVkeHUh?=
HH MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm0TWM2OD1zMUGuNFghdk1? M{D2V3NCVkeHUh?=
MHH-PREB-1 MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TTcGlEPTB;MUG0MlMhdk1? NFq5fnFUSU6JRWK=
NCI-H1770 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mne0TWM2OD1zMkOuPFYhdk1? NIq3fFRUSU6JRWK=
HuO9 NYTiV4tkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojvTWM2OD1{ME[uNFIhdk1? M{\wbHNCVkeHUh?=
HAL-01 NWfiXHJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETsS5ZKSzVyPUKwOk44OyCwTR?= MVHTRW5ITVJ?
NOS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJzMT64NkBvVQ>? MXTTRW5ITVJ?
HGC-27 M4H4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTJzMj61O{BvVQ>? MoC2V2FPT0WU
NB69 NULkb4N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DGWWlEPTB;MkS1MlI4KG6P MnuwV2FPT0WU
RS4-11 NFXITGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJ4MT63OkBvVQ>? NHLndYJUSU6JRWK=
DOK MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2S0fWlEPTB;M{CxMlchdk1? NFu5d3NUSU6JRWK=
LB2241-RCC M{TJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTNyMz64OEBvVQ>? NGH0TllUSU6JRWK=
NCI-H1623 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInp[HBKSzVyPUOwOE4xQCCwTR?= NVnFZoVoW0GQR1XS
YH-13 MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jwcmlEPTB;M{C0MlMzKG6P NXnRe4t4W0GQR1XS
BPH-1 M133UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2H5fGlEPTB;M{G0JI5O NF\ueXZUSU6JRWK=
AN3-CA MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC5TWM2OD1|NECuN|chdk1? M3\SSHNCVkeHUh?=
ES7 M{HVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGi2bpVKSzVyPUO0NU46QSCwTR?= NWjtU29[W0GQR1XS
MDA-MB-175-VII NYHZeoFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L2[GlEPTB;M{WyMlkzKG6P NFW2fFhUSU6JRWK=
GAMG MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTN5MD64OUBvVQ>? MmrMV2FPT0WU
CHL-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTN5OD62OUBvVQ>? NH;3WZpUSU6JRWK=
NB7 MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTN6OT64N{BvVQ>? NXe1cWhGW0GQR1XS
MFE-280 NXG5cnp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoC1TWM2OD12MUiuNkBvVQ>? MYDTRW5ITVJ?
HL-60 MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjUcHJKSzVyPUSyOU44PSCwTR?= M2naUHNCVkeHUh?=
GCIY MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTR|Mz64JI5O M{LVPHNCVkeHUh?=
MDA-MB-361 M17RSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR|OT6xN{BvVQ>? NXTFUotCW0GQR1XS
LXF-289 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXflXWtIUUN3ME20OFgvOjdibl2= NUjXVIRSW0GQR1XS
NBsusSR MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rCVmlEPTB;NEi4Mlg2KG6P M37OVHNCVkeHUh?=
KU-19-19 NGfJW2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK2[2JKSzVyPUWxOk4xPyCwTR?= NVe4OVlsW0GQR1XS
A204 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDMSphKSzVyPUWyNk4{OyCwTR?= NHL0RplUSU6JRWK=
LB1047-RCC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTV{Mj65N{BvVQ>? NH;yRo9USU6JRWK=
COLO-684 Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{C1e2lEPTB;NUKzMlEyKG6P NH3kPHNUSU6JRWK=
PA-1 NFH2VpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTV|Mj60NUBvVQ>? MWDTRW5ITVJ?
MG-63 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fwbmlEPTB;NUSxMlEyKG6P NHPxTYdUSU6JRWK=
BHT-101 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnVO2tKSzVyPUW0OE46PCCwTR?= M{HtSnNCVkeHUh?=
NKM-1 NYHyT3drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPqUFhHUUN3ME21PVMvODlibl2= M{D2eXNCVkeHUh?=
T47D MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTnPGZtUUN3ME21PVcvPTZibl2= NUXV[4Z[W0GQR1XS
MOLT-4 MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnHVI5KSzVyPU[yN{43OiCwTR?= MmTpV2FPT0WU
IGROV-1 MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjpbpJKSzVyPU[zOE4{OSCwTR?= NEXLUpRUSU6JRWK=
ES4 NYjUe5d2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XPemlEPTB;NkO5MlU1KG6P M3PKNHNCVkeHUh?=
HuO-3N1 MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTZ2Mj6zPEBvVQ>? MWPTRW5ITVJ?
NEC8 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTCT2VHUUN3ME22OVMvPTdibl2= NXjMOm17W0GQR1XS
HO-1-N-1 NHHaN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DXdGlEPTB;NkW5MlE4KG6P MXHTRW5ITVJ?
EPCL-272H M2LTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\TTWM2OD14OEeuNlEhdk1? MoHOV2FPT0WU
D-263MG MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\zUWpKSzVyPUexPE4yKG6P NHPrV3JUSU6JRWK=
MV-4-11 NGjoNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojDTWM2OD15MkSuN|Ehdk1? MXXTRW5ITVJ?
SK-NEP-1 MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHGWHpSUUN3ME23NlUvQTRibl2= NX6zPWtZW0GQR1XS
SW872 M3:zOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\IdYlKSzVyPUeyO{45QSCwTR?= NUjqNZV7W0GQR1XS
P30-OHK MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ftVmlEPTB;N{OwMlcyKG6P MlzVV2FPT0WU
OMC-1 MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPq[YhbUUN3ME23OVEvODlibl2= NEWzcG5USU6JRWK=
LoVo MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHkTWM2OD15N{euPUBvVQ>? MkHpV2FPT0WU
LNCaP-Clone-FGC NELJbWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHXc49KSzVyPUe5Ok4{PCCwTR?= MoTEV2FPT0WU
L-363 NHnRZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP0TWM2OD15OUiuOFIhdk1? MkjhV2FPT0WU
ES8 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HwbmlEPTB;OEGwMlUzKG6P MUfTRW5ITVJ?
697 NFnqd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfjUow3UUN3ME24N|EvPTVibl2= MWTTRW5ITVJ?
HSC-3 MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LkeWlEPTB;OEO5MlU1KG6P MXvTRW5ITVJ?
H4 NXqyWIlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjKbVBkUUN3ME24OVAvQDVibl2= Mlj3V2FPT0WU
QIMR-WIL MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnjW4JKSzVyPUi2OU4zKG6P MUfTRW5ITVJ?
OAW-42 NEnR[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTh5Mj6xPUBvVQ>? NF;KUGFUSU6JRWK=
MCF7 NHTzWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTZTWM2OD16OUiuOVkhdk1? NYPUbVdPW0GQR1XS
SCC-25 M1jpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHJN4tvUUN3ME25NVQvOTlibl2= NGXpXmtUSU6JRWK=
NCI-H1563 MoD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTlzNT65PUBvVQ>? MWTTRW5ITVJ?
OVCAR-5 NYPRTmtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIq3b5BKSzVyPUm0NE4yPyCwTR?= NG\LeGVUSU6JRWK=
HDLM-2 MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUOyVHpPUUN3ME25OFkvOiCwTR?= NIP0R|ZUSU6JRWK=
NB5 M2fZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTl3Nj62JI5O NIPj[4NUSU6JRWK=
NCI-H292 NXfGSZk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTGZWI2UUN3ME25O|QvOzJibl2= NV3vPGhjW0GQR1XS
A101D MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPEfWhKSzVyPUm5NE4yQSCwTR?= Ml\qV2FPT0WU
NCI-H1648 NGiz[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\sd|ZqUUN3ME25PVgvPTFibl2= NVf6dFZqW0GQR1XS
EKVX NXr1bmdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkOxTWM2OD1zLkCxNlkh|ryP NVqzbJFHW0GQR1XS
SW1710 M1;1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7yTWM2OD1zLkC0NlM{KM7:TR?= NHOz[YlUSU6JRWK=
WM-115 NHjJZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFwME[2OVYh|ryP M17GenNCVkeHUh?=
CAL-54 NFf1dlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;INmlEPTB;MT6wO|A5OSEQvF2= MYPTRW5ITVJ?
TGBC24TKB MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\p[WlEPTB;MT6wPFA1PSEQvF2= NGTBcWJUSU6JRWK=
NCI-H520 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP2UIRKSzVyPUGuNFg6PjdizszN M4njfHNCVkeHUh?=
D-423MG M4XjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn6XJNwUUN3ME2xMlA6QTZ{IN88US=> M2HsVnNCVkeHUh?=
BFTC-905 M1X1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\vTWlEPTB;MT6xN|Q1QSEQvF2= MUTTRW5ITVJ?
HT NYHafoFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LsWmlEPTB;MT6xN|Q4QCEQvF2= NEHFU|dUSU6JRWK=
CTB-1 NYO3[mY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfzbHRKSzVyPUGuNVQzQTNizszN NEHBRolUSU6JRWK=
Hs-578-T Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFwMUm1OlUh|ryP MlHuV2FPT0WU
HuH-7 M4frT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS1[pM2UUN3ME2xMlIxQTR7IN88US=> NVTmTYo2W0GQR1XS
LB996-RCC MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDYXopKSzVyPUGuNlIyPzdizszN NYnrfpRJW0GQR1XS
KYSE-270 MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P1TWlEPTB;MT6yPVc{PCEQvF2= NHjGSGdUSU6JRWK=
A4-Fuk NVLXUIxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2WyS2lEPTB;MT6yPVk6OyEQvF2= NVvy[2NTW0GQR1XS
A498 NInBUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTFwM{C0O|Qh|ryP MXTTRW5ITVJ?
SK-MEL-1 NXPCVVlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[5e5N[UUN3ME2xMlMxPjd7IN88US=> NGPUUG1USU6JRWK=
AU565 Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjocIlKSzVyPUGuN|E5PjNizszN NWDyVGNqW0GQR1XS
Saos-2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS2TWM2OD1zLkOzNlA2KM7:TR?= NVq1e4dZW0GQR1XS
A549 M{HlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PaSGlEPTB;MT6zPVk4KM7:TR?= M3rPbXNCVkeHUh?=
BFTC-909 NXT0OXNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwNEOzNFUh|ryP NI\LRnZUSU6JRWK=
MDA-MB-415 NHPRZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\ReWlEPTB;MT60PFY6OiEQvF2= M1HnVHNCVkeHUh?=
639-V MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHLTWM2OD1zLkWwNlQ2KM7:TR?= NI\WPJlUSU6JRWK=
A704 Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjubolLUUN3ME2xMlUxPzh3IN88US=> NV74cVVCW0GQR1XS
PANC-03-27 MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LibWlEPTB;MT61NVQxQCEQvF2= M2PxOHNCVkeHUh?=
SK-MEL-28 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnuOG81UUN3ME2xMlU3ODh3IN88US=> MkT3V2FPT0WU
Ramos-2G6-4C10 NXLoNFdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPIPXcyUUN3ME2xMlYxPzR4IN88US=> MnTnV2FPT0WU
HuP-T4 NXL2UmQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DSdWlEPTB;MT62NFc4QCEQvF2= M4juc3NCVkeHUh?=
VA-ES-BJ NITod4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvsTWM2OD1zLk[xNlch|ryP NWPmNG5XW0GQR1XS
EFM-19 M2LLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFwNkG4NUDPxE1? NVfGd5F7W0GQR1XS
G-401 NXjxO3NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTFwNkKxOlQh|ryP MXvTRW5ITVJ?
D-566MG M2HPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnUTWM2OD1zLk[yOVMh|ryP M4jrdHNCVkeHUh?=
JVM-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HsWmlEPTB;MT62OFg4PSEQvF2= NV\yO|RWW0GQR1XS
TK10 M2fnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXm2d4FMUUN3ME2xMlY4ODh|IN88US=> M2fkfHNCVkeHUh?=
BT-20 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;Ebm5KUUN3ME2xMlY5QTB{IN88US=> Ml\FV2FPT0WU
EGI-1 NEHBc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfXTWM2OD1zLki0O|AyKM7:TR?= NHPIW49USU6JRWK=
EW-16 MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFwOEWxPFIh|ryP NV\MN3J7W0GQR1XS
NCI-H2228 NFTHcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\ETWM2OD1zLki1NlA{KM7:TR?= NUPIOm1pW0GQR1XS
BB49-HNC MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrsO4NKSzVyPUGuPFg3QTJizszN M33LU3NCVkeHUh?=
G-402 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnDVIhCUUN3ME2xMlg6Pzl5IN88US=> NVXJV41LW0GQR1XS
NCI-H526 M4Hl[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHWwZZBKSzVyPUGuPVE{QSEQvF2= MkLoV2FPT0WU
ME-180 NI\1PFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3rTWM2OD1zLkmzOFc4KM7:TR?= M4TiXXNCVkeHUh?=
PFSK-1 Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf2TWM2OD1zLkm0OFU5KM7:TR?= Mke1V2FPT0WU
TYK-nu NXfPb|JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fBd2lEPTB;MT65OVgzOyEQvF2= M1XyPHNCVkeHUh?=
HOS M16wOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnMTWM2OD1zLkm3PVQ5KM7:TR?= NF\Hdm1USU6JRWK=
T98G NWPpUVZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M330RmlEPTB;MT65PVAxPiEQvF2= NEXy[VlUSU6JRWK=
SK-MES-1 NVS5R|hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\NU|BOUUN3ME2yMlAyOzN{IN88US=> MWrTRW5ITVJ?
SNB75 M4Didmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\pUG9CUUN3ME2yMlAyPTRzIN88US=> MXzTRW5ITVJ?
LAMA-84 M3qyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHseXdDUUN3ME2yMlAzPjh7IN88US=> NWXOWGlrW0GQR1XS
CAL-39 NYflbml1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXRcYx6UUN3ME2yMlA{OjhizszN MUjTRW5ITVJ?
LOXIMVI NHTPUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3QTWM2OD1{LkC0NFg1KM7:TR?= NXHXXIJvW0GQR1XS
NH-12 Ml3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPtTWM2OD1{LkC1OFI1KM7:TR?= M4PTcXNCVkeHUh?=
NCI-H1048 NYH5bXFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL6WWVFUUN3ME2yMlExPTJizszN MWfTRW5ITVJ?
KS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\te2J{UUN3ME2yMlEyODBzIN88US=> MlyzV2FPT0WU
NCI-N87 NITROHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJwMUOzPFQh|ryP M3eyOXNCVkeHUh?=
CHP-212 MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3KTWM2OD1{LkG4OFQzKM7:TR?= MnjuV2FPT0WU
HCC1419 Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrmWlZKSzVyPUKuNlEyOTVizszN MkTYV2FPT0WU
ES1 NUnsZ2prT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTyb4FpUUN3ME2yMlIyOzJ4IN88US=> NVHGd2JtW0GQR1XS
NCI-H2030 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHri[2VKSzVyPUKuNlQyOjNizszN NVzlZoVPW0GQR1XS
EW-22 Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XaeWlEPTB;Mj6yOVA3PyEQvF2= M{HWbnNCVkeHUh?=
A431 MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rKWWlEPTB;Mj6yO|M2PCEQvF2= MUnTRW5ITVJ?
SF126 Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LMVWlEPTB;Mj6zNFYzPSEQvF2= NEeyb3JUSU6JRWK=
SF295 NEXyO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID3UYpKSzVyPUKuN|E2OjRizszN Mn6wV2FPT0WU
D-502MG MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJwM{K0OlEh|ryP MmPWV2FPT0WU
HCC2157 NVHuRW1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHQNYFFUUN3ME2yMlMzQTJ5IN88US=> M3f1fnNCVkeHUh?=
D-283MED MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1iy[WlEPTB;Mj6zOVkzPiEQvF2= MWTTRW5ITVJ?
SNU-423 NFjSd|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJwNECxO|Eh|ryP M1;6enNCVkeHUh?=
SK-LU-1 NHuzfpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJwNES1PFYh|ryP MmLJV2FPT0WU
22RV1 M1nvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXwV2ZKSzVyPUKuOFU3OTdizszN NYDrbJl2W0GQR1XS
SW1088 NHTNSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrYPVVKSzVyPUKuOFkzOTNizszN MkTSV2FPT0WU
HT-3 NUi2SVl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jrdWlEPTB;Mj60PVI2QSEQvF2= M3XsVnNCVkeHUh?=
NCI-H1666 M4CzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\3VFhKSzVyPUKuOVEyODRizszN MUfTRW5ITVJ?
EM-2 NV7UVIpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJwNUGxOlkh|ryP MlfnV2FPT0WU
SNU-449 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTsTWM2OD1{LkW3NFE1KM7:TR?= MkiwV2FPT0WU
786-0 Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1X6c2lEPTB;Mj61PVI{QCEQvF2= NVLRTZVEW0GQR1XS
SKG-IIIa NFTYVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrrb3BKSzVyPUKuOlU6OzlizszN NHroSJBUSU6JRWK=
MEL-HO MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJwNke2N|Qh|ryP M2nSXXNCVkeHUh?=
LCLC-97TM1 Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DhdGlEPTB;Mj62PVI3PyEQvF2= Ml7mV2FPT0WU
MKN7 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPuTWM2OD1{LkewO|U1KM7:TR?= Mmj3V2FPT0WU
5637 MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojtTWM2OD1{LkexNFM2KM7:TR?= MXvTRW5ITVJ?
HOP-92 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPvPFJKSzVyPUKuO|Q4OTdizszN NXTieHJxW0GQR1XS
MDA-MB-157 M3;hOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFr1[GFKSzVyPUKuPFIxOjNizszN MX;TRW5ITVJ?
NB12 NYTYNmJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXCTWM2OD1{Lki0PVE1KM7:TR?= M1ni[nNCVkeHUh?=
DMS-273 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJwOE[0O{DPxE1? M4HEOHNCVkeHUh?=
HCC70 NYDpelFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzteYdDUUN3ME2yMlg3PTh7IN88US=> MYHTRW5ITVJ?
YKG-1 NHjF[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTNwMEO3PFch|ryP M2\XOXNCVkeHUh?=
NCI-H28 NYXnWng6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK4TWM2OD1|LkC1NlkyKM7:TR?= M2DhW3NCVkeHUh?=
HN NFrlZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HUO2lEPTB;Mz6wOlY{PiEQvF2= MWPTRW5ITVJ?
HT-1080 M1\kUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmflTWM2OD1|LkC4OlA3KM7:TR?= MmLTV2FPT0WU
HPAF-II NXHxVXY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTNwMUCwOlgh|ryP M3\ObHNCVkeHUh?=
U-2-OS M4Tt[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHUTWM2OD1|LkGzO|gzKM7:TR?= NF3VfFZUSU6JRWK=
SNU-387 NHLBTlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjMTWM2OD1|LkG2N|Y1KM7:TR?= MnnYV2FPT0WU
Becker M3TmVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLHTWM2OD1|LkG2PFA5KM7:TR?= M2CxdXNCVkeHUh?=
BHY NHHreXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTNwMkW1O|Eh|ryP NF\kfIxUSU6JRWK=
HTC-C3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvHU29KSzVyPUOuNlk{PTJizszN MX;TRW5ITVJ?
M14 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTNwM{C2OlMh|ryP MXLTRW5ITVJ?
COR-L23 M2e4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC2TWM2OD1|LkO3Nlc6KM7:TR?= NVO4b|VZW0GQR1XS
C32 NETiZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTNwNEG1NFgh|ryP NX3vendHW0GQR1XS
Mewo NX\nTVRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO0fXhKSzVyPUOuOFIyQDJizszN MWLTRW5ITVJ?
TE-8 M17IO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3jOpdKSzVyPUOuOFgzPTlizszN NIO4TnFUSU6JRWK=
RPMI-2650 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj4RpFPUUN3ME2zMlYxPjN5IN88US=> MkK5V2FPT0WU
AGS NFjTUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\DVJo1UUN3ME2zMlYzPDZ2IN88US=> NVH6d4FiW0GQR1XS
MZ2-MEL M4\H[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXyNIJ5UUN3ME2zMlY3OTN6IN88US=> MWPTRW5ITVJ?
Calu-3 NHfadJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nMZmlEPTB;Mz63NVI5PyEQvF2= NIfodlBUSU6JRWK=
SJSA-1 NUn0eZp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL4OFhKSzVyPUOuO|E{OTVizszN Mn3oV2FPT0WU
SW962 M1\jemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fzbmlEPTB;Mz63NlY{PiEQvF2= MV;TRW5ITVJ?
PC-14 NVzRNlZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7QRW9KSzVyPUOuO|MzOjJizszN MXnTRW5ITVJ?
SW1573 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWT2bXlRUUN3ME2zMlc2OzR6IN88US=> NWW1TJlFW0GQR1XS
769-P NWXTdGwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTNwOEK3OFMh|ryP NIW4SolUSU6JRWK=
KNS-62 M1HFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDmXXZZUUN3ME2zMlkzOzN6IN88US=> NV;nU2E4W0GQR1XS
NCI-H747 NFrtbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXyTWM2OD12LkC1OlM5KM7:TR?= NXK5U3FkW0GQR1XS
LN-405 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTRwMUW3Nlgh|ryP NWHLN5dqW0GQR1XS
OVCAR-8 NXv4U49mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHlc3pPUUN3ME20MlIzPTR|IN88US=> NUPabZdYW0GQR1XS
DMS-114 MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTRwMkO4PVEh|ryP MX\TRW5ITVJ?
NCI-H2126 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XXTmlEPTB;ND6yOFU2QCEQvF2= NXjvdY01W0GQR1XS
TCCSUP MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTRwMkS3PFgh|ryP NXn1Z3hGW0GQR1XS
SK-N-FI NWS4O3piT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTRwMkWzN|Ih|ryP MXvTRW5ITVJ?
HCE-4 NV7Ud4lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIeyOnpKSzVyPUSuNlcyQTdizszN NVrMPWNoW0GQR1XS
DK-MG Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;CUWNKSzVyPUSuN|A{QSEQvF2= NUTYPFRDW0GQR1XS
RO82-W-1 M3;4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLqTnZKSzVyPUSuN|I2QDRizszN M1ryfXNCVkeHUh?=
A2780 MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTRwM{[2PFIh|ryP M{X0S3NCVkeHUh?=
ETK-1 NIDk[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PWNmlEPTB;ND6zO|A2OiEQvF2= NX\XdZdxW0GQR1XS
FADU NUTwRpAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTRwM{e0Olch|ryP NWrwOZhXW0GQR1XS
CAL-12T NGr3WJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCwTWM2OD12LkSxOFE{KM7:TR?= NHjQZ5ZUSU6JRWK=
647-V MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jTSmlEPTB;ND60OFAzOiEQvF2= NEm0THVUSU6JRWK=
TGBC1TKB NWTuOm5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH5T2dKSzVyPUSuOFUyOTNizszN MmjsV2FPT0WU
LU-99A NWXCfFIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPiSow4UUN3ME20MlQ3ODZizszN M{i5dXNCVkeHUh?=
CAL-33 NXTQN2t3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTRwNUK0OVYh|ryP MUDTRW5ITVJ?
LU-134-A NFHleXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3u3d2lEPTB;ND61Nlc1PSEQvF2= M2\ZTnNCVkeHUh?=
NCI-H1355 NVXWemRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rUdmlEPTB;ND61OVE1PiEQvF2= M{jtR3NCVkeHUh?=
RPMI-7951 NYHHflVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHuSHJKSzVyPUSuOVcxODJizszN M1T5PHNCVkeHUh?=
TE-1 MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTRwNk[xOFMh|ryP Mn\zV2FPT0WU
OE33 NIWzZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTRwN{C1NVEh|ryP NFHyNmtUSU6JRWK=
CAL-51 NVXXd2ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2D1fWlEPTB;ND63NVA5OiEQvF2= MXfTRW5ITVJ?
SW1783 M1q2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DlOGlEPTB;ND63OVMxQCEQvF2= NGXEe41USU6JRWK=
BT-474 M4j1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTRwN{[zPFQh|ryP M1qwbXNCVkeHUh?=
KYSE-520 M3r4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrXUnVJUUN3ME20Mlg4Ozl{IN88US=> MW\TRW5ITVJ?
8-MG-BA MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\vflVSUUN3ME20Mlg5PTV5IN88US=> NUDidHl1W0GQR1XS
IA-LM NYW1U4RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTRwOUm0N|Uh|ryP MWDTRW5ITVJ?
SW954 MlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorSTWM2OD12Lkm5OFQ{KM7:TR?= MXjTRW5ITVJ?
RPMI-8226 NIHTRphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rXZWlEPTB;NT6wOVQ3OSEQvF2= M2P0VHNCVkeHUh?=
MKN1 NUO4Z4xUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTVwMEe5Nlch|ryP MXLTRW5ITVJ?
A375 M1rsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULrbFlVUUN3ME21MlA6OjV4IN88US=> MYDTRW5ITVJ?
8305C M{HUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjpdJVKSzVyPUWuNFk5QDdizszN MYDTRW5ITVJ?
CAL-62 Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTVwMUiyOVkh|ryP M1v3Z3NCVkeHUh?=
NB10 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G1SmlEPTB;NT6yNlc1PCEQvF2= NH6yXldUSU6JRWK=
OC-314 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonNTWM2OD13LkO3OFQ1KM7:TR?= NVfpXJplW0GQR1XS
PSN1 NXPBSmpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7DeopvUUN3ME21MlM5Ojh4IN88US=> NV;nWHViW0GQR1XS
GR-ST M3rqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTVwM{izNlIh|ryP NF3Db3JUSU6JRWK=
P12-ICHIKAWA MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPGeGpUUUN3ME21MlQxOSEQvF2= NFXGd|BUSU6JRWK=
NCI-H1092 NIHUO|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jrc2lEPTB;NT60NVE1QCEQvF2= NF\4NHJUSU6JRWK=
SCC-4 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTVwNEGzOVUh|ryP MVjTRW5ITVJ?
TE-6 NEHwOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i2OWlEPTB;NT60NVgyPiEQvF2= NGHvXHRUSU6JRWK=
DOHH-2 M4Hv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[xU2xSUUN3ME21MlQzOjR6IN88US=> NFnRdFJUSU6JRWK=
SW684 MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXMenpPUUN3ME21MlY3Ozh3IN88US=> NEHjOFlUSU6JRWK=
CP50-MEL-B M{nUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHxXVJKSzVyPUWuOlg3QDRizszN MmXWV2FPT0WU
UM-UC-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTVwN{KyN|Eh|ryP NGHyNIVUSU6JRWK=
LC-2-ad NUnCRZJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjlUWpKSzVyPUWuO|gzPTFizszN M2PWSnNCVkeHUh?=
PC-3 M{\EPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vKU2lEPTB;NT65NVYyPSEQvF2= NUjVVI5iW0GQR1XS
CAN M{PaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7YVHdKSzVyPUWuPVI5OiEQvF2= NGnvdW9USU6JRWK=
ESS-1 M1rGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTVwOUe4Olkh|ryP NUHVTG11W0GQR1XS
ATN-1 M1zhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTZwMEW1Olgh|ryP MUPTRW5ITVJ?
BxPC-3 NV22S4tyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XqO2lEPTB;Nj6wPFIyQSEQvF2= NXy3To8zW0GQR1XS
KYSE-150 M4WwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnK2TWM2OD14LkGyOFc3KM7:TR?= NIKxOIdUSU6JRWK=
RPMI-8866 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTZwMUmxOlMh|ryP Mn[1V2FPT0WU
SW780 Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTZwMkC0NkDPxE1? NGPjZYJUSU6JRWK=
A388 NIPrSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjIVHpIUUN3ME22MlI{OTF3IN88US=> M2LhOHNCVkeHUh?=
NCI-H1437 M3XB[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LXOGlEPTB;Nj6yOFA4OyEQvF2= NWrzc2hLW0GQR1XS
NCI-H1755 NVnNdZdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHwTWM2OD14LkO2OlEzKM7:TR?= M4DJU3NCVkeHUh?=
LS-123 M{P5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPFTWM2OD14LkSwOVIyKM7:TR?= NW\qUWhtW0GQR1XS
CaR-1 MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPXdFRlUUN3ME22MlQ3Ozd|IN88US=> NH;CRnJUSU6JRWK=
RT-112 M1e3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnqXItKSzVyPU[uOlA{OzhizszN NVmwdGwyW0GQR1XS
CGT NVfSfIFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\0W2lEPTB;Nj63N|Y5OSEQvF2= MXvTRW5ITVJ?
SW626 MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\vUGlEPTB;Nj63N|k1PiEQvF2= NVPXUppxW0GQR1XS
AsPC-1 MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{OxdmlEPTB;Nj63OFUxPyEQvF2= MV;TRW5ITVJ?
SBC-5 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\UWWlEPTB;Nj65O|I6PyEQvF2= M2j4enNCVkeHUh?=
SF539 M3HUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rNXWlEPTB;Nj65PVM{OyEQvF2= M36wcXNCVkeHUh?=
TI-73 NWH2b495T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkC3TWM2OD15LkC2Nlg2KM7:TR?= MnjTV2FPT0WU
MHH-ES-1 MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfzTWM2OD15LkC3O|YzKM7:TR?= MlnzV2FPT0WU
KYSE-510 MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTdwMEi0N|Ih|ryP NH3jXVNUSU6JRWK=
EW-1 Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfZTVQ5UUN3ME23MlM3QTl4IN88US=> NEf6fWRUSU6JRWK=
SK-OV-3 NGXNTodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj6WHFKSzVyPUeuN|k1OzJizszN NES2OVBUSU6JRWK=
MC-IXC M3P5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Pk[2lEPTB;Nz60NVk4OiEQvF2= MWHTRW5ITVJ?
HSC-2 M13pOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDZTWM2OD15LkSyO|A2KM7:TR?= MX;TRW5ITVJ?
NCI-H2342 M3vOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPMTWM2OD15LkWxOFkh|ryP MXHTRW5ITVJ?
NCI-H1792 NHjHcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;sfWlEPTB;Nz61NVcyOSEQvF2= MYTTRW5ITVJ?
HT-1376 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTdwOEe3O|gh|ryP NXHpN4txW0GQR1XS
EW-13 MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTdwOEm5O|ch|ryP MVvTRW5ITVJ?
no-11 NEPGU3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPKV|JKSzVyPUeuPVAyPzRizszN MY\TRW5ITVJ?
Daoy NGXH[WJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvTOHpKSzVyPUeuPVQ{OjFizszN M2XD[nNCVkeHUh?=
COLO-800 NWDqNXFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3zTWM2OD16LkC0NVYzKM7:TR?= MoqxV2FPT0WU
GB-1 Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRThwME[1OlUh|ryP MUXTRW5ITVJ?
SJRH30 NUDie|lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTiUItMUUN3ME24MlE2QDd6IN88US=> MnHTV2FPT0WU
NCI-H2291 NVLzd5RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRThwMkmxPFch|ryP NXnUb2o6W0GQR1XS
J82 NXP0Z4tXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHJeVU6UUN3ME24MlI6PDlzIN88US=> MljrV2FPT0WU
NCI-H596 NFe3U|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfYTWM2OD16LkOxOFU{KM7:TR?= M{[yeXNCVkeHUh?=
RERF-LC-MS MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rr[2lEPTB;OD6zOFg2PiEQvF2= NYH0XXF2W0GQR1XS
RH-18 NI\GXYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRThwM{WwOFYh|ryP NVXPdoY3W0GQR1XS
SW48 NHXpU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRThwNUm0OVMh|ryP NY[2bZNKW0GQR1XS
RD Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\zTWM2OD16LkW5N|kyKM7:TR?= NHTCXGJUSU6JRWK=
MS-1 M3n6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;mWmlEPTB;OD62NVM5PyEQvF2= MVfTRW5ITVJ?
ES6 MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\E[YhEUUN3ME24Mlc{OTF7IN88US=> Ml;UV2FPT0WU
TE-12 MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;oZmlEPTB;OD63O|UxPSEQvF2= MYXTRW5ITVJ?
DBTRG-05MG M2rWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXvRlZKSzVyPUiuPVEzOTdizszN NHHGbo9USU6JRWK=
KINGS-1 MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HGU2lEPTB;OD65Nlk{QCEQvF2= M{X6cnNCVkeHUh?=
HLE MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXoe|RKSzVyPUiuPVM4QDVizszN NYP0bW5JW0GQR1XS
MHH-NB-11 M3v3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLsTWM2OD17LkCxPFM6KM7:TR?= MXzTRW5ITVJ?
U-87-MG NHrkUJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPh[5o1UUN3ME25MlI1OzJzIN88US=> MljYV2FPT0WU
MN-60 NH3P[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[3SJBKSzVyPUmuNlQ2PDJizszN M2nqdnNCVkeHUh?=
SAS M17oN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTlwMkW1PFEh|ryP M4r0PHNCVkeHUh?=
NCI-H446 NUXETnJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\OXnZKSzVyPUmuN|YyKM7:TR?= MWLTRW5ITVJ?
C-33-A MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTlwNEO5PFgh|ryP MnjFV2FPT0WU
RXF393 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrZeIdlUUN3ME25MlQ4ODB{IN88US=> Ml\DV2FPT0WU
CGTH-W-1 M{LlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoW0TWM2OD17LkS5N|g1KM7:TR?= NXT4VYtTW0GQR1XS
RCM-1 NX21foM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;Z[FBrUUN3ME25MlY{QDBzIN88US=> NHv4RmJUSU6JRWK=
SN12C NUPlZlFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorwTWM2OD17Lk[1N|M5KM7:TR?= NWezXXA3W0GQR1XS
KLE MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\rWI41UUN3ME25MlcxODB7IN88US=> Mo[1V2FPT0WU
EFO-21 M1;wbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTzTWM2OD17Lke3N|gzKM7:TR?= M1nNb3NCVkeHUh?=
KYSE-70 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmi0TWM2OD17Lki4NFEyKM7:TR?= NFHNeXJUSU6JRWK=
D-247MG MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\nW5ZKSzVyPUGwMlA2PjhizszN M3X3XHNCVkeHUh?=
MPP-89 MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;BVmlEPTB;MUCuNFk1PiEQvF2= MUfTRW5ITVJ?
RVH-421 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPaRVZoUUN3ME2xNE4yPTB3IN88US=> NIqxWWtUSU6JRWK=
NCI-H460 NX3qSIlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFyLkK4NFYh|ryP NYfYfWRjW0GQR1XS
NOMO-1 M{HLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnraTWM2OD1zMD6zOVMzKM7:TR?= M1\tS3NCVkeHUh?=
DEL NHjCNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVztcXZRUUN3ME2xNE4{Pzl2IN88US=> MYPTRW5ITVJ?
HT55 NYfJU4p2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Th[2lEPTB;MUCuOlIxPSEQvF2= NXfaZY46W0GQR1XS
MC116 NIGwZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTFyLk[2OVUh|ryP MX7TRW5ITVJ?
BB30-HNC Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3iTWM2OD1zMD62Olkh|ryP MnLRV2FPT0WU
DJM-1 NGPaVXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlWxTWM2OD1zMD62PVQ6KM7:TR?= NEjzZVJUSU6JRWK=
ZR-75-30 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFyLkm0OFEh|ryP M1XiWHNCVkeHUh?=
U-118-MG NVLJeXJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm2SYNKSzVyPUGwMlk5QTZizszN NFX2b3JUSU6JRWK=
MSTO-211H Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnIe4RKSzVyPUGxMlA4OTZizszN NV\PNmE6W0GQR1XS
SW837 M2SwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTFzLkC5OFkh|ryP MX3TRW5ITVJ?
HuCCT1 NXHTfFk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHj4fVNKSzVyPUGxMlEzQDFizszN NGfmc5BUSU6JRWK=
RCC10RGB Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T3R2lEPTB;MUGuNVM2KM7:TR?= MVTTRW5ITVJ?
NMC-G1 NHvkO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXGOFlZUUN3ME2xNU4yPDl|IN88US=> MnO2V2FPT0WU
NCI-H650 MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHlTWM2OD1zMT6zO|k1KM7:TR?= MUTTRW5ITVJ?
HEC-1 M2jtc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjWWXFEUUN3ME2xNU41OzJ6IN88US=> MlzEV2FPT0WU
DU-4475 NWHBRmJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX6TWM2OD1zMT63N|k{KM7:TR?= NWLwZmI4W0GQR1XS
DSH1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFzLke2NFYh|ryP M{Xi[nNCVkeHUh?=
HCC1569 M{jIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\wTFh7UUN3ME2xNU44Pjd6IN88US=> MULTRW5ITVJ?
HCC1187 NWO1VlVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzVVZFKSzVyPUGxMlg2QDhizszN MnmwV2FPT0WU
EW-11 NH;XNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHWW2dKSzVyPUGxMlk1PzRizszN NYq0em81W0GQR1XS
LB2518-MEL NWXZR|VuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XvZmlEPTB;MUKuNFU6KM7:TR?= MmDjV2FPT0WU
KALS-1 NYfFelZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID6UWVKSzVyPUGyMlg2PTNizszN NETaNGxUSU6JRWK=
8505C M3;sN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\CdIl6UUN3ME2xNk45QDVizszN NYr6ZW85W0GQR1XS
SK-N-DZ MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLHTWM2OD1zMz6wOFU{KM7:TR?= MYXTRW5ITVJ?
CHP-134 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjyOmZOUUN3ME2xN{4yOTV6IN88US=> MnXlV2FPT0WU
HCE-T NV:0WoNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF|LkKzOlQh|ryP NXvSXHl3W0GQR1XS
LB-831-BLC Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD6eWV6UUN3ME2xN{43OjR4IN88US=> NVrPZVJKW0GQR1XS
OVCAR-4 Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnZWItpUUN3ME2xN{43PTJ2IN88US=> MmLiV2FPT0WU
SW756 NH20NGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTF|LkeyOFYh|ryP MWjTRW5ITVJ?
OCUB-M M{\R[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K4TWlEPTB;MUOuPFE2PiEQvF2= MVvTRW5ITVJ?
SW982 NUDzPI9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXreVlKSzVyPUGzMlgzPzZizszN NW\1OocxW0GQR1XS
DB NIn4fYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnpTWM2OD1zMz64N|g1KM7:TR?= NFnYOYtUSU6JRWK=
H-EMC-SS M{nkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHzZoQyUUN3ME2xN{46OTN7IN88US=> M2HqT3NCVkeHUh?=
VMRC-RCZ NEf2VlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF2LkCwNVUh|ryP Mn7CV2FPT0WU
CAKI-1 M4LoeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTF2LkCxN|Ih|ryP MVzTRW5ITVJ?
GI-1 M3u0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjldWJKSzVyPUG0MlA3PThizszN M4GwZXNCVkeHUh?=
Ca9-22 NYDhZpVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnNZm5KSzVyPUG0MlYxPTRizszN MWrTRW5ITVJ?
TE-5 NFm0XmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvReIRGUUN3ME2xOE44OjB6IN88US=> Mn3SV2FPT0WU
EFO-27 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvY[GRKSzVyPUG0Mlc3OjJizszN NYDhTI5rW0GQR1XS
CAL-72 MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTF2Lke3PFMh|ryP NEL5eolUSU6JRWK=
GP5d MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\pdWJKSzVyPUG1MlA1PzRizszN M2\VUnNCVkeHUh?=
CAS-1 Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm1flZMUUN3ME2xOU4xPjZizszN NHjld3pUSU6JRWK=
A2058 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DVPWlEPTB;MUWuOVY{QCEQvF2= M2f5THNCVkeHUh?=
PANC-08-13 NF\OOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXaRlB4UUN3ME2xOU43QDV7IN88US=> NUXHVGNZW0GQR1XS
Detroit562 NXXYW3FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHyzc5pKSzVyPUG1MlkyOzlizszN MlTZV2FPT0WU
PANC-10-05 NGmyWpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF4LkC4NlEh|ryP NIeyXXdUSU6JRWK=
KOSC-2 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjVW4FiUUN3ME2xOk4yOTJ3IN88US=> NYHUd2x1W0GQR1XS
GT3TKB NEnkZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fsO2lEPTB;MU[uNVk5OSEQvF2= NYfzflI4W0GQR1XS
KM-H2 NFWzeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTF4LkO2OFYh|ryP M4HiZ3NCVkeHUh?=
LB771-HNC NEjkcZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHqUIxKSzVyPUG2MlQ1OjJizszN NHrHbFhUSU6JRWK=
SF268 NHXlNGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF4LkS1NkDPxE1? MWTTRW5ITVJ?
OE19 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF4LkWyOEDPxE1? NGLoc4ZUSU6JRWK=
MLMA NIPNS|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TQTGlEPTB;MU[uOVU4OSEQvF2= M1u4enNCVkeHUh?=
MDA-MB-231 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\4TWM2OD1zNj63NVM3KM7:TR?= MWXTRW5ITVJ?
TGW NG\oN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{GxS2lEPTB;MU[uPFExOiEQvF2= MWDTRW5ITVJ?
MDA-MB-453 NEPVXZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTF5LkCwNFMh|ryP Ml\NV2FPT0WU
SNU-C2B Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Da[GlEPTB;MUeuNFI{PyEQvF2= MXHTRW5ITVJ?
A427 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnmyTWM2OD1zNz6yN|M1KM7:TR?= M4XYN3NCVkeHUh?=
SK-MEL-2 M2nZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWi0cYxJUUN3ME2xO{4{OjF|IN88US=> NGr4[5pUSU6JRWK=
KURAMOCHI MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF5LkO4PVch|ryP MYHTRW5ITVJ?
IST-MEL1 MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTF5LkmxPFIh|ryP NEnMeZlUSU6JRWK=
NCI-H1793 NHvzTXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTF6LkG1PFEh|ryP NWnDO|NEW0GQR1XS
HCC1395 NXTLUnlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LDdmlEPTB;MUiuOVYyOSEQvF2= NGPM[nhUSU6JRWK=
NUGC-3 MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrUTIxKSzVyPUG4MlY2QDRizszN MVzTRW5ITVJ?
BB65-RCC M1Xkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF6Lk[2PUDPxE1? NVXEVo1sW0GQR1XS
RMG-I MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\aT2lEPTB;MUiuO|M5OiEQvF2= MmnJV2FPT0WU
LS-513 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\RNnVKSzVyPUG4MlkzOjhizszN NEPxVllUSU6JRWK=
MFM-223 MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETrdYRKSzVyPUG5MlA4OTZizszN MnPYV2FPT0WU
NCI-H727 NV2weZRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;HTWM2OD1zOT6zNlk2KM7:TR?= Moj5V2FPT0WU
KP-4 NH:3fm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XKfGlEPTB;MUmuPFU{OSEQvF2= NY\weFV1W0GQR1XS
NB13 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF7Lki4N|kh|ryP MWPTRW5ITVJ?
UACC-893 NF3semZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF7Lkm3OVch|ryP NEDwbm1USU6JRWK=
HT-1197 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDhbY1KSzVyPUKwMlI6PThizszN NWrWVWQ1W0GQR1XS
NCI-H2029 MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJyLkOyOlYh|ryP NE\FdIlUSU6JRWK=
GI-ME-N NHvMSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIixZ3RKSzVyPUKwMlM{PzNizszN NIHC[2FUSU6JRWK=
OVCAR-3 NXzybZhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[2N4lKSzVyPUKwMlU5OjJizszN M1;TOnNCVkeHUh?=
HD-MY-Z MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLYTWM2OD1{MT6zOlk3KM7:TR?= NF;LOGpUSU6JRWK=
NTERA-S-cl-D1 M1LLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jlfWlEPTB;MkGuOlczOiEQvF2= MlTnV2FPT0WU
SCH NVvNcoFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe2b2JLUUN3ME2yNk41QTZizszN NWToW3N5W0GQR1XS
KARPAS-299 NULqSZp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnryTWM2OD1{Mz6zPFg4KM7:TR?= NGHqU4ZUSU6JRWK=
NCI-H1650 NFi4SmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfSTWM2OD1{Mz65NlQyKM7:TR?= NHXEV5ZUSU6JRWK=
ACHN NVH1VGtvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXCTWM2OD1{ND60OlU3KM7:TR?= Ml3EV2FPT0WU
M059J NXrHSWh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTiT4xTUUN3ME2yOE42PjN2IN88US=> MnL6V2FPT0WU
AM-38 NYfEdppnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3m4T2lEPTB;MkWuOFgyKM7:TR?= MYnTRW5ITVJ?
KG-1 NXXIcYZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJ3LkW0PVQh|ryP M{DFR3NCVkeHUh?=
COLO-824 NWPoeWQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD0S4VKSzVyPUK1MlU2QTlizszN M4rjdHNCVkeHUh?=
NCI-H1155 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\nTWM2OD1{NT61PFQ4KM7:TR?= NVixZZpTW0GQR1XS
NCI-H441 NImyRVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S3VGlEPTB;MkWuO|Q3PSEQvF2= NILHXo1USU6JRWK=
J-RT3-T3-5 NXG4UZlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTMPXB1UUN3ME2yOk4{ODJ5IN88US=> MkHBV2FPT0WU
JEG-3 NWT4c29[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJ4Lk[4NFUh|ryP MWLTRW5ITVJ?
RKO NVXzW3o6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUD2NJVzUUN3ME2yOk44PjN{IN88US=> MmnYV2FPT0WU
CAL-85-1 NXzvcY0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXlbppKSzVyPUK3MlIyOThizszN M2rHdHNCVkeHUh?=
CAL-120 NFjTfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7iUIVKSzVyPUK3MlY6OTRizszN M2PYd3NCVkeHUh?=
NCI-H2452 NUHFOXhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfQcIhKSzVyPUK3Mlc4OTZizszN Mlq5V2FPT0WU
NCI-H1395 NYPORmpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJ5Lke4N|Mh|ryP M3XSTHNCVkeHUh?=
KYSE-450 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJ5Lkm4OlIh|ryP MnLpV2FPT0WU
S-117 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJ7LkO4OVch|ryP MWXTRW5ITVJ?
SW13 NUn1SmNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnQTZZ5UUN3ME2yPU45PTF7IN88US=> M1r1bXNCVkeHUh?=
ES3 M4S0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnuUot[UUN3ME2zNE4{PzN|IN88US=> NWOwTWhUW0GQR1XS
HCT-116 M{mwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u1ZWlEPTB;M{CuOVU2PCEQvF2= MUTTRW5ITVJ?
NCI-H1693 NFK1VWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXkTWM2OD1|MD61PVQzKM7:TR?= MULTRW5ITVJ?
VM-CUB-1 NV;sXodWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi2WG5KSzVyPUOwMlY1OTNizszN MmrOV2FPT0WU
NCI-H2170 MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr6SYpKSzVyPUOxMlU4QDRizszN MnXHV2FPT0WU
ALL-PO NF3pd49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTNzLki0Nlgh|ryP M2i2fnNCVkeHUh?=
NCI-H661 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LOcGlEPTB;M{KuNFYzOyEQvF2= MlvVV2FPT0WU
NCI-H2347 NGmw[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHYflJKSzVyPUOyMlQ5OzdizszN NFXRW|hUSU6JRWK=
FTC-133 MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTN{LkewOkDPxE1? MVnTRW5ITVJ?
COLO-829 NVfHV2hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[1[29KSzVyPUOzMlM1PjdizszN MVPTRW5ITVJ?
GOTO Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L1eWlEPTB;M{OuOVI2QCEQvF2= M2jGSXNCVkeHUh?=
YAPC NFeye3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTN|LkixOVkh|ryP MmnYV2FPT0WU
LCLC-103H NH7tOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TIUWlEPTB;M{SuNVYzPCEQvF2= MUDTRW5ITVJ?
SiHa NW\vZVQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\KTWM2OD1|ND6zPFE4KM7:TR?= NGrvSFNUSU6JRWK=
LK-2 NFrse29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTN2LkW3NFgh|ryP MUjTRW5ITVJ?
KP-N-YS MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fHfWlEPTB;M{SuO|IxOiEQvF2= M2\p[3NCVkeHUh?=
NCI-SNU-1 M4LDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDkNpNJUUN3ME2zOU4yPzlizszN M1Oz[3NCVkeHUh?=
KNS-81-FD NX[1RlhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Tsb2lEPTB;M{WuOlY{KM7:TR?= M4G5Z3NCVkeHUh?=
SCC-9 MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\XPGlEPTB;M{[uO|E1PiEQvF2= MX\TRW5ITVJ?
SH-4 NIXsc|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnpfJhKSzVyPUO2Mlc{KM7:TR?= MV3TRW5ITVJ?
HCC-1954 MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3WTWM2OD1|Nz6yO|I6KM7:TR?= Mk[zV2FPT0WU
BALL-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7aTWM2OD1|Nz61N|E3KM7:TR?= NWPufpBUW0GQR1XS
BE-13 NEXJeJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELvU2xKSzVyPUO3MlcxOThizszN MnrWV2FPT0WU
COLO-678 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTN5Lkm0N|ch|ryP M13KXXNCVkeHUh?=
SK-MEL-3 MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES5[ohKSzVyPUO4MlI{QTdizszN MWLTRW5ITVJ?
OAW-28 MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDKTWM2OD1|OD62N|kh|ryP MVHTRW5ITVJ?
CAMA-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TjbWlEPTB;M{iuPVY6OSEQvF2= MYXTRW5ITVJ?
C2BBe1 MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTN7LkixPEDPxE1? NHnYSHpUSU6JRWK=
A3-KAW NY\qZo1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HOcmlEPTB;NECuN|Y3OSEQvF2= NIiyXYJUSU6JRWK=
SK-MEL-24 NX62XVBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIewO|JKSzVyPUSwMlU6OzFizszN NW\NWnpTW0GQR1XS
KYSE-140 NET6SG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DrdGlEPTB;NECuO|E3PSEQvF2= M4riNHNCVkeHUh?=
MOLT-16 MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nad2lEPTB;NEGuNVU{PiEQvF2= M1zxWnNCVkeHUh?=
CFPAC-1 M4\RNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37NWGlEPTB;NEKuOVIyOSEQvF2= M2TwPXNCVkeHUh?=
NB14 NUDpboRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnVWFltUUN3ME20Nk44ODJ5IN88US=> NFPXVVlUSU6JRWK=
COLO-792 M3G3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUeybYp1UUN3ME20Nk45QTZzIN88US=> MVfTRW5ITVJ?
RH-1 NGDaSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTR|LkS4N|Yh|ryP NWLyWnNsW0GQR1XS
NCI-H522 M1LGVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTR2LkO1Olgh|ryP NI\mbXRUSU6JRWK=
Ca-Ski M1ThTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTiWG5mUUN3ME20OE45OTF2IN88US=> M3u2fXNCVkeHUh?=
KGN NHjvPWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW1bmpKSzVyPUS4MlMxPjNizszN MkizV2FPT0WU
UACC-62 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLsSok5UUN3ME20PE41ODd{IN88US=> NGTMc5dUSU6JRWK=
NCI-H358 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjLXYZKSzVyPUS5MlMxOThizszN M{K4bXNCVkeHUh?=
LS-411N MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\WfpFKSzVyPUS5MlMyOThizszN MWDTRW5ITVJ?
IST-MES1 NF;2d3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPSXmJ5UUN3ME20PU42PjJ3IN88US=> MnnjV2FPT0WU

... Click to View More Cell Line Experimental Data
体内研究 在微粒体中，GDC-0941仅有有限的代谢，其口服生物利用度为78%[5]。GDC-0941 每天按 75 mg/kg剂量处理携带人U87MG 恶性胶质移植瘤的雌性NCr无胸腺小鼠，显著抑制生长，肿瘤生长抑制率为 83%。[1]GDC-0941 每天按 150 mg/kg剂量口服处理携带HER2扩增的抗Trastuzumab的MDA-MB-361.1移植瘤 的小鼠，抑制肿瘤生长，且显著延迟肿瘤衰退，与肿瘤中强诱导型凋亡相关。[2] GDC-0941 每天按75 mg/kg剂量处理携带自发性B细胞滤泡性淋巴瘤的PTEN+/-LKB1+/hypo小鼠，持续2周，诱导肿瘤体积下降~40%，伴随着AKT, S6K 和SGK(血清和糖皮质激素蛋白激酶)蛋白激酶的磷酸化被切除。GDC-0941抑制肿瘤细胞增殖，诱导凋亡和抑制中心母细胞数。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：

[1]
+ 展开

闪烁接近检测:

使用p85α调节亚基，使重组人PI3Kα, PI3Kβ, 和PI3Kδ在 Sf9 杆状病毒系统中共表达，在谷胱甘肽-琼脂糖凝胶上进行亲和层析而纯化GST-融合蛋白。重组人 PI3Kγ表达作为单体 GST融合，也想上述相似方法纯化。GDC-0941 溶于DMSO，加到含200 μg硅酸钇(Ysi) 聚赖氨酸SPA 磁珠, 4 mM MgCl2, 1 mM 二硫苏糖醇 (DTT), 1 μM ATP, 0.125 μCi [γ-33P]-ATP, 和4% (v/v) DMSO的20 mM Tris-HCl (pH 7.5)上，总体积为 50 μL。PI3Kα (5 ng), PI3Kβ(5 ng), PI3Kδ(5 ng), 或PI3Kγ(5 ng)的重组GST-融合 ，加到实验混合物中，开始激酶反应。在室温下温育1小时后, 加入150 μL PBS终止反应。混合物在2000 rpm 转速下离心2分钟，然后使用Wallac Microbeta计数器读数。在 MDL Assay Explorer系统中使用S型，剂量-反应曲线，计算进行至少2次独立重复实验，取平均值，作为IC50值。
细胞实验：

[2]
+ 展开
  • Cell lines: SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, 和MKN-7
  • Concentrations: 溶于DMSO,终浓度为~10 μM
  • Incubation Time: 48,和72小时
  • Method:

    使用不同浓度 GDC-0941处理细胞48,和 72小时。通过CellTiter-Glo Luminescent细胞活性检测实验测定细胞增殖/活力。通过Western Blot分析pAKT (Ser473), cleaved caspase-3, 和cleaved PARP通过 Caspase-Glo 3/7实验和细胞死亡检测 ELISAplus 实验分别测定caspase 3/7活性, 和凋亡。


    (Only for Reference)
动物实验：

[2]
+ 展开
  • Animal Models: 移植MDA-MB-361.1细胞的NCR裸鼠, 皮下移植BT474-M1 细胞的SCID, C.B-17/IcrHsd-Prkdcscid 小鼠
  • Formulation: 溶于10% DMSO, 5% Tween-20, 85% 水
  • Dosages: ~150 mg/kg/day
  • Administration: 口服饲喂
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 44 mg/mL (85.66 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
2% DMSO+30% PEG 300+5% Tween 80+ddH2O 		5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 513.64
化学式

C23H27N7O3S2
CAS号 957054-30-7
稳定性 powder
in solvent
别名 RG7321

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01740336 Completed Breast Cancer Genentech Inc. February 6 2013 Phase 2
NCT00999128 Completed Healthy Volunteers Genentech Inc. October 26 2009 Phase 1
NCT02092831 Completed Healthy Volunteer Genentech Inc. April 2014 Phase 1
NCT01474668 Completed Healthy Volunteer Genentech Inc. October 2011 Phase 1
NCT01437566 Completed Breast Cancer Genentech Inc. October 2011 Phase 2
NCT01240226 Completed Healthy Volunteer Genentech Inc. November 2010 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项
Selleck产品目录册

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

  • 泛PI3K抑制剂

    LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.

  • 活性最高的PI3K抑制剂

    Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.

  • FDA批准的PI3K抑制剂

    CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.

  • 最新的PI3K抑制剂

    GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

相关PI3K产品

  • Taselisib (GDC 0032) New

    Taselisib (GDC 0032)是一种有效，下一代的β亚型PI3K抑制剂，作用于PI3Kα/δ/γ， IC50分别为0.29 nM/0.12 nM/0.97nM，比作用于PI3Kβ选择性高10倍以上。

  • Pilaralisib (XL147) New

    Pilaralisib (XL147)是一种选择性的可逆I型PI3K抑制剂，作用于PI3Kα/δ/γ，在无细胞试验中IC50为 39 nM/36 nM/23 nM，对PI3Kβ作用较低。Phase 1/2。

  • GNE-317 New

    GNE-317 是一种有效的，大脑渗透性 PI3K 抑制剂。

  • LY294002

    LY294002 是首个合成的已知抑制PI3Kα/δ/β的小分子，在无细胞测定中IC50分别为 0.5 μM/0.57 μM/0.97 μM；在溶液中比在Wortmannin中稳定，也能够阻断自噬体的形成。它不仅能够结合class I PI3Ks和其他PI3K相关的激酶，还能够结合一些与PI3K家族无关的新型靶点。

    Features:LY294002是选择性的, 可渗透细胞的特定PI3K抑制剂，可作用于酶的ATP结合位点，且抑制自体吞噬的螯合作用。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA)是一种选择性PI3K抑制剂，作用于Vps34和PI3Kγ，在 HeLa细胞中IC50分别为25 μM和60 μM；永久性抑制I型PI3K，但对III型PI3K的抑制是短暂的，也会阻断自噬体的形成。

  • Idelalisib (CAL-101, GS-1101)

    Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂，在无细胞试验中IC50为 2.5 nM；对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍，对p110δ的选择性是对 C2β，hVPS34，DNA-PK 和 mTOR的400到4000倍。

    Features:Calistoga 暗示 CAL-101治疗血液恶性肿瘤可能有更广泛的应用价值。

  • Wortmannin

    Wortmannin是一种首次命名的PI3K抑制剂，在无细胞试验中IC50为3 nM，对 PI3K 家族的选择性较低。也会抑制自噬体的形成，并有效抑制DNA-PK/ATM，在无细胞试验中IC50为16 nM和150 nM。

  • Dactolisib (BEZ235, NVP-BEZ235)

    Dactolisib (BEZ235, NVP-BEZ235) 是一种双重ATP竞争性 PI3K 和 mTOR 抑制剂，在无细胞试验中，抑制 p110α/γ/δ/β 和 mTOR(p70S6K) 的 IC50 分别为 4 nM /5 nM /7 nM /75 nM /6 nM。 在 3T3TopBP1-ER 细胞中抑制 ATR，IC50 为 21 nM，而对 Akt 和 PDK1 的抑制作用很弱。Phase 2。

  • Buparlisib (BKM120, NVP-BKM120)

    Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂，在无细胞试验中作用于p110α/β/δ/γ的IC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34，mTOR，DNAPK 的作用效果下降，而对 PI4Kβ几乎没有活性。Phase 2。

    Features:BKM120是可用于口服的生物有效的PI3K抑制剂。

  • Alpelisib (BYL719)

    Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂，在无细胞试验中IC50为 5 nM，对PI3Kβ/γ/δ具有极弱的作用。Phase 2。

Tags: 购买Pictilisib (GDC-0941) | Pictilisib (GDC-0941)供应商 | 采购Pictilisib (GDC-0941) | Pictilisib (GDC-0941)价格 | Pictilisib (GDC-0941)生产 | 订购Pictilisib (GDC-0941) | Pictilisib (GDC-0941)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID